This article presents the results of evaluating the possibility of conducting radio astronomy studies in the windows of atmospheric transparency ~100, ~230, and ~350 GHz using the optical Big Telescope Alt-Azimuthal (BTA) of the Special Astrophysical Observatory of the Russian Academy of Sciences (SAO RAS). A list of some promising astronomical tasks is proposed. The astroclimat conditions at the BTA site and possible optical, cryogenic, and mechanical interfaces for mounting a superconducting radio receiver at the focus of the optical telescope are considered.
View Article and Find Full Text PDFLong-term prophylaxis with a von Willebrand factor (VWF) concentrate is recommended in patients with von Willebrand disease (VWD) who have a history of severe and frequent bleeds. However, data from prospective studies are scarce. WIL-31, a prospective, noncontrolled, international phase 3 trial, investigated the efficacy and safety of Wilate prophylaxis in severe patients with VWD.
View Article and Find Full Text PDFImmune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. This subgroup analysis reports prospective interim data for patients treated with a plasma-derived, von Willebrand factor-stabilized FVIII concentrate (pdFVIII/VWF, octanate).
View Article and Find Full Text PDFInterval stability is a novel method for the study of complex dynamical systems, allowing for the estimation of their stability to strong perturbations. This method describes how large perturbation should be to disrupt the stable dynamical regime of the system (attractor). In our work, interval stability is used for the first time to study the properties of a real natural system: to analyze the stability of the earth's climate system during the last 2.
View Article and Find Full Text PDFIntroduction: FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant FVIII produced in a human cell line.
Methods: The NuProtect study investigated the immunogenicity of simoctocog alfa in PUPs.